共 223 条
[1]
Albain KS(2002)Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest oncology group phase II study, SWOG 9019 J Clin Oncol 20 3454-3460
[2]
Crowley JJ(2011)Peptide receptor radionuclide therapy with Eur J Nucl Med Mol Imaging 38 2125-2135
[3]
Turrisi AT(2016)Lu-DOTATATE: the IEO phase I-II study Eur J Nucl Med Mol Imaging 43 839-851
[4]
Gandara DR(2017)Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors JAMA Oncol 3 1335-1342
[5]
Farrar WB(2014)Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States Pancreas 43 518-525
[6]
Clark JI(2017)Peptide receptor radionuclide therapy with Eur J Nucl Med Mol Imaging 44 1490-1500
[7]
Beasley KR(2018)Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience Eur J Nucl Med Mol Imaging 46 728-742
[8]
Livingston RB(2014)Personalized Eur J Nucl Med Mol Imaging 41 925-933
[9]
Bodei L(2015)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study Cancer 121 589-597
[10]
Cremonesi M(2017)Personalized Clin Nucl Med 42 436-443